BRAMLETTE, T. B., LAWSON, D. H., WASHINGTON, C. V., VELEDAR, E., JOHNS, B. R., BRISMAN, S. F., … CHEN, S. C. (2007). Interferon Alfa-2b or Not 2b? Significant Differences Exist in the Decision-Making Process between Melanoma Patients Who Accept or Decline High-Dose Adjuvant Interferon Alfa-2b Treatment. Dermatologic Surgery, 33(1), 11–16. https://doi.org/10.1097/00042728-200701000-00002

BRAMLETTE, TRACY B., DAVID H. LAWSON, CARL V. WASHINGTON, E. M. I. R. VELEDAR, BARRY R. JOHNS, STACEY F. BRISMAN, L. I. A. N. A. ABRAMOVA, and SUEPHY C. CHEN. “Interferon Alfa-2b or Not 2b? Significant Differences Exist in the Decision-Making Process between Melanoma Patients Who Accept or Decline High-Dose Adjuvant Interferon Alfa-2b Treatment.” Dermatologic Surgery 33, no. 1 (January 2007): 11–16. https://doi.org/10.1097/00042728-200701000-00002.

BRAMLETTE TB, LAWSON DH, WASHINGTON CV, VELEDAR E, JOHNS BR, BRISMAN SF, et al. Interferon Alfa-2b or Not 2b? Significant Differences Exist in the Decision-Making Process between Melanoma Patients Who Accept or Decline High-Dose Adjuvant Interferon Alfa-2b Treatment. Dermatologic Surgery. 2007 Jan;33(1):11–6.

BRAMLETTE, TRACY B., et al. “Interferon Alfa-2b or Not 2b? Significant Differences Exist in the Decision-Making Process between Melanoma Patients Who Accept or Decline High-Dose Adjuvant Interferon Alfa-2b Treatment.” Dermatologic Surgery, vol. 33, no. 1, Ovid Technologies (Wolters Kluwer Health), Jan. 2007, pp. 11–16. Crossref, doi:10.1097/00042728-200701000-00002.

BRAMLETTE TB, LAWSON DH, WASHINGTON CV, VELEDAR E, JOHNS BR, BRISMAN SF, ABRAMOVA L, CHEN SC. Interferon Alfa-2b or Not 2b? Significant Differences Exist in the Decision-Making Process between Melanoma Patients Who Accept or Decline High-Dose Adjuvant Interferon Alfa-2b Treatment. Dermatologic Surgery. Ovid Technologies (Wolters Kluwer Health); 2007 Jan;33(1):11–16.